Oseltamivir Free Base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413986

CAS#: 196618-13-0 (free base)

Description: Oseltamivir Free Base is an acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE. It is used in Influenza treatment


Chemical Structure

img
Oseltamivir Free Base
CAS# 196618-13-0 (free base)

Theoretical Analysis

MedKoo Cat#: 413986
Name: Oseltamivir Free Base
CAS#: 196618-13-0 (free base)
Chemical Formula: C16H28N2O4
Exact Mass: 312.2049
Molecular Weight: 312.41
Elemental Analysis: C, 61.51; H, 9.03; N, 8.97; O, 20.48

Price and Availability

Size Price Availability Quantity
100.0mg USD 450.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1650.0 2 Weeks
Bulk inquiry

Related CAS #: 204255-11-8 (phosphate); 196618-13-0 (free base)   204255-09-4 (HCl)    

Synonym: Oseltamivir Free Base; GS4104; GS-4104; GS 4104

IUPAC/Chemical Name: 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-

InChi Key: VSZGPKBBMSAYNT-RRFJBIMHSA-N

InChi Code: InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1

SMILES Code: O=C(C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1)OCC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 312.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Esposito S, Principi N. Oseltamivir for influenza infection in children: risks and benefits. Expert Rev Respir Med. 2016;10(1):79-87. doi: 10.1586/17476348.2016.1126182. Epub 2015 Dec 19. PMID: 26616633.

2: Tagarro A, Cruz-Cañete M, Otheo E, Launes C, Couceiro JA, Pérez C, Alfayate S; en nombre del Grupo de trabajo de Infecciones Respiratorias de la Sociedad Española de Infectología Pediátrica (SEIP); Miembros del Grupo de Trabajo de Infecciones Respiratorias de la SEIP que han participado en la revisión del manuscrito. Oseltamivir para el tratamiento de la gripe en niños y adolescentes [Oseltamivir for the treatment of influenza in children and adolescents]. An Pediatr (Barc). 2019 May;90(5):317.e1-317.e8. Spanish. doi: 10.1016/j.anpedi.2019.01.009. Epub 2019 Feb 21. PMID: 30797703.

3: Doshi P, Heneghan C, Jefferson T. Oseltamivir for influenza. Lancet. 2016 Jan 9;387(10014):124. doi: 10.1016/S0140-6736(15)01282-9. Epub 2016 Jan 8. PMID: 26841993.

4: Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, Francis NA, Lewis RJ, Godycki-Cwirko M, Llor C, Chlabicz S, Lionis C, Seifert B, Sundvall PD, Colliers A, Aabenhus R, Bjerrum L, Jonassen Harbin N, Lindbæk M, Glinz D, Bucher HC, Kovács B, Radzeviciene Jurgute R, Touboul Lundgren P, Little P, Murphy AW, De Sutter A, Openshaw P, de Jong MD, Connor JT, Matheeussen V, Ieven M, Goossens H, Verheij TJ. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020 Jan 4;395(10217):42-52. doi: 10.1016/S0140-6736(19)32982-4. Epub 2019 Dec 12. PMID: 31839279.

5: Ono H. [Hypothermic Action of Oseltamivir Not Dependent on Its Anti-influenza Virus Action]. Yakugaku Zasshi. 2019;139(5):767-781. Japanese. doi: 10.1248/yakushi.18-00191. PMID: 31061347.

6: Lee J, Park JH, Jwa H, Kim YH. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Med J. 2017 Jul;58(4):778-785. doi: 10.3349/ymj.2017.58.4.778. PMID: 28540991; PMCID: PMC5447109.

7: Yun YL, Gao SH, Wen Y, Wang ZP, Miao HJ, Chen WS. Bioequivalence of two oseltamivir formulations in healthy Chinese volunteers
. Int J Clin Pharmacol Ther. 2017 Sep;55(9):761-768. doi: 10.5414/CP202926. PMID: 28737128.

8: Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1688-1698. doi: 10.1093/infdis/jiz656. PMID: 31822885.

9: Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018 May 2;66(10):1492-1500. doi: 10.1093/cid/cix1040. PMID: 29186364.

10: Rech MA. Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment? Pharmacotherapy. 2020 Mar;40(3):182-185. doi: 10.1002/phar.2370. Epub 2020 Feb 12. PMID: 32048321.